logo

Liminal Biosciences Inc. (LMNL)



Trade LMNL now with
  Date
  Headline
5/23/2022 8:29:08 AM Liminal BioSciences : First Subject Dosed In Phase 1a Single Ascending Dose Clinical Trial Of Fezagepras
5/23/2022 8:07:06 AM Liminal BioSciences Announces First Subject Dosed In Phase 1a Single Ascending Dose Clinical Trial Of Fezagepras
3/14/2022 8:10:16 AM Liminal BioSciences Says PK Data Shows Fezagepras Has Nitrogen Scavenging Properties
8/9/2021 7:33:35 AM Liminal BioSciences To Sell Its Rare Pediatric Disease Priority Review Voucher For $105 Mln
6/23/2021 8:31:53 AM Liminal BioSciences Inks Share Purchase Agreement For Sale Of Remaining Plasma-derived Business With Kedrion
6/4/2021 3:44:45 PM Liminal BioSciences Announces FDA Approval For Its Biologics License Application For Ryplazim
5/17/2021 8:42:36 AM Liminal BioSciences Enters Agreement With Kedrion To Divest Plasma Collection And Plasma-Derived Therapeutics Business
1/12/2021 9:13:14 AM Liminal BioSciences Gets FDA Approval For US-based Plasma Collection Center
7/30/2015 9:17:08 AM RBC Capital Markets Initiates ProMetic Life Sciences Inc. (PLI.TO) At Outperform With C$3.50 Price Target